Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
(NQ: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News
Press releases about
 
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Alkermes plc Launches Corporate Operations in Ireland
September 19, 2011
from Business Wire News Releases
Alkermes plc and Elan Corporation plc Announce Completion of Merger Between Alkermes, Inc. and Elan Drug Technologies
September 16, 2011
from Business Wire News Releases
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
September 12, 2011
from Business Wire News Releases
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
September 12, 2011
Composite Endpoint Included Body Weight, Blood Pressure and Lipid Levels Read More
from PR Newswire
Alkermes Announces Shareholder Vote in Favor of Merger with Elan Drug Technologies
September 08, 2011
from Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences
September 07, 2011
from Business Wire News Releases
Equity Research on Alkermes Inc. and Hospira Inc. - Drug Delivery Sector's Relationship With the FDA
September 01, 2011
from Marketwired News Releases
Alkermes’ Corporate Presentation to Be Webcast at Baird’s 2011 Health Care Conference
August 31, 2011
from Business Wire News Releases
Factors Moving Markets, Worldwide View - Equity Research on Alkermes, Inc. and Forest Laboratories, Inc.
August 25, 2011
from Marketwired News Releases
BYDUREON™ FDA Action Date Set for January 28, 2012
August 10, 2011
from Business Wire News Releases
BYDUREON™ FDA ACTION DATE SET FOR JANUARY 28, 2012
August 10, 2011
from PR Newswire
The Zacks Analyst Blog Highlights: Alkermes, Johnson & Johnson, Amylin Pharmaceuticals, Eli Lilly and Company and Elan Corporation
August 04, 2011
from PR Newswire
Alkermes Reports First Quarter Fiscal 2012 Financial Results
August 01, 2011
from Business Wire News Releases
BYDUREON™ Reply Submitted to FDA
July 28, 2011
from Business Wire News Releases
BYDUREON™ Reply Submitted to FDA
July 28, 2011
New PDUFA Action Date Expected Within 14 Days, per FDA Guidelines Read More
from PR Newswire
Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2012
July 25, 2011
from Business Wire News Releases
Alkermes Provides Outlook for Alkermes plc and Update on Advancing Product Portfolio at Analyst and Investor Day
July 18, 2011
from Business Wire News Releases
The Zacks Analyst Blog Highlights: Alkermes, Amylin Pharmaceuticals, Eli Lilly and Company, Liberty Property Trust and Duke Realty
July 13, 2011
from PR Newswire
Critical Insider Trading Found at a Microsoft Stock Price Between US$93.10 - US$97.34
July 13, 2011
from PR Newswire
Alkermes to Webcast Analyst and Investor Day
July 11, 2011
from Business Wire News Releases
Exenatide tQT Study Showed No Prolongation of QT Interval
July 07, 2011
from Business Wire News Releases
Exenatide tQT Study Showed No Prolongation of QT Interval
July 07, 2011
Results to be Included in BYDUREON™ New Drug Application Resubmission in the Third Quarter of 2011 Read More
from PR Newswire
Alkermes Announces Results from Phase 2 Study of ALKS 33 for Treatment of Binge Eating Disorder
July 07, 2011
from Business Wire News Releases
Research on Alkermes Inc. and Hospira Inc. - Drug Delivery Companies Looking for New Revenues
June 30, 2011
from Marketwired News Releases
Alkermes Announces Positive Results from Clinical Study of ALKS 9070 For Treatment of Schizophrenia
June 30, 2011
from Business Wire News Releases
Financial Services Sector Report: Large Insider Sale of American Express
June 29, 2011
from PR Newswire
Pharmacoeconomic Value of Addiction Treatments, Including VIVITROL®, Published in Leading Healthcare Policy Journal
June 27, 2011
from Business Wire News Releases
Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
June 24, 2011
from Business Wire News Releases
Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
June 24, 2011
from Business Wire News Releases
Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011
June 24, 2011
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here